In venetoclax-treated AML, the presence of IDH2 mutation, as well as elevated blast cell percentage in peripheral blood or bone marrow associated with response, presence of PTPN11, TET2 or ASXL1 mutation indicated lack of response, while FLT3, NPM1, RUNX1, and TP53 status as well as CD34 levels were not associated with treatment response (Figure 6). Here, RUNX1 is linked to acute myeloid leukemia.